These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. C-terminal truncation of α-synuclein alters DNA structure from extension to compaction. Jiang K; Rocha S; Kumar R; Westerlund F; Wittung-Stafshede P Biochem Biophys Res Commun; 2021 Sep; 568():43-47. PubMed ID: 34175689 [TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? Pozo Devoto VM; Falzone TL Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016 [TBL] [Abstract][Full Text] [Related]
12. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187 [TBL] [Abstract][Full Text] [Related]
13. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease. Vella LJ; Hill AF; Cheng L Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304 [TBL] [Abstract][Full Text] [Related]
14. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. Galvagnion C J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142 [TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088 [TBL] [Abstract][Full Text] [Related]
16. Crosstalk Between Alpha-Synuclein and Other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson's Disease. Werner T; Horvath I; Wittung-Stafshede P J Parkinsons Dis; 2020; 10(3):819-830. PubMed ID: 32538869 [TBL] [Abstract][Full Text] [Related]
17. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
18. Interaction between Copper Chaperone Atox1 and Parkinson's Disease Protein α-Synuclein Includes Metal-Binding Sites and Occurs in Living Cells. Horvath I; Blockhuys S; Šulskis D; Holgersson S; Kumar R; Burmann BM; Wittung-Stafshede P ACS Chem Neurosci; 2019 Nov; 10(11):4659-4668. PubMed ID: 31600047 [TBL] [Abstract][Full Text] [Related]
19. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. Falsone SF; Kungl AJ; Rek A; Cappai R; Zangger K J Biol Chem; 2009 Nov; 284(45):31190-9. PubMed ID: 19759002 [TBL] [Abstract][Full Text] [Related]
20. The yin and yang of amyloid: insights from α-synuclein and repeat domain of Pmel17. McGlinchey RP; Yap TL; Lee JC Phys Chem Chem Phys; 2011 Dec; 13(45):20066-75. PubMed ID: 21993592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]